Prediction of underestimated invasiveness in patients with ductal carcinoma insitu of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy

Breast

Volumn 22, Issue 4, 2013, Pages 537-542

  Schulz, Sophie ^a   Sinn, Peter ^a   Golatta, Michael ^a   Rauch, Geraldine ^a   Junkermann, Hans ^a   Schuetz, Florian ^a   Sohn, Christof ^a   Heil, Joerg ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biopsy, needle; Breast neoplasms; Carcinoma, intraductal, noninfiltrating; Diagnostic errors; Sentinel lymph node biopsy

Indexed keywords

ADULT; AGED; ARTICLE; BREAST IMAGING REPORTING AND DATA SYSTEM; CANCER PATIENT; CANCER RISK; CLINICAL EXAMINATION; ECHOMAMMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEPENDENT VARIABLE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PERCUTANEOUS BIOPSY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM; SENTINEL LYMPH NODE BIOPSY; TUMOR INVASION; TUMOR VOLUME;

EID: 84879783263     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.11.002     Document Type: Article

References (25)

1. Jackman R.J., Burbank F., Parker S.H., Evans W.P., Lechner M.C., Richardson T.R., et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001, 218(2):497-502.
2. King T.A., Farr G.H., Cederbom G.J., Smetherman D.H., Bolton J.S., Stolier A.J., et al. Amass on breast imaging predicts coexisting invasive carcinoma in patients with a core biopsy diagnosis of ductal carcinoma in situ. Am Surg 2001, 67(9):907-912.
3. Wahedna Y., Evans A.J., Pinder S.E., Ellis I.O., Blamey R.W., Geraghty J.G. Mammographic size of ductal carcinoma in situ does not predict the presence of an invasive focus. Eur J Cancer 2001, 37(4):459-462.
4. Hoorntje L.E., Schipper M.E., Peeters P.H., Bellot F., Storm R.K., Borel Rinkes I.H. The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 2003, 10(7):748-753.
5. Goyal A., Douglas-Jones A., Monypenny I., Sweetland H., Stevens G., Mansel R.E. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat 2006, 98(3):311-314.
6. Huo L., Sneige N., Hunt K.K., Albarracin C.T., Lopez A., Resetkova E. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 2006, 107(8):1760-1768.
7. Houssami N., Ciatto S., Ellis I., Ambrogetti D. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer 2007, 109(3):487-495.
8. Meijnen P., Oldenburg H.S., Loo C.E., Nieweg O.E., Peterse J.L., Rutgers E.J. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg 2007, 94(8):952-956.
9. Rutstein L.A., Johnson R.R., Poller W.R., Dabbs D., Groblewski J., Rakitt T., et al. Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ. Breast J 2007, 13(3):251-257.
10. Tan J.C., McCready D.R., Easson A.M., Leong W.L. Role of sentinel lymph node biopsy in ductal carcinoma-in-situ treated by mastectomy. Ann Surg Oncol 2007, 14(2):638-645.
11. Dominguez F.J., Golshan M., Black D.M., Hughes K.S., Gadd M.A., Christian R., et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 2008, 15(1):268-273.
12. Kurniawan E.D., Rose A., Mou A., Buchanan M., Collins J.P., Wong M.H., et al. Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg 2010, 145(11):1098-1104.
13. Han J.S., Molberg K.H., Sarode V. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J 2011, 17(3):223-229.
14. Houssami N., Ambrogetti D., Marinovich M.L., Bianchi S., Macaskill P., Vezzosi V., et al. Accuracy of a preoperative model for predicting invasive breast cancer in women with ductal carcinoma-in-situ on vacuum-assisted core needle biopsy. Ann Surg Oncol 2011, 18(5):1364-1371.
15. Miyake T., Shimazu K., Ohashi H., Taguchi T., Ueda S., Nakayama T., et al. Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ. Am J Surg 2011, 202(1):59-65.
16. Feldman S.M., Krag D.N., McNally R.K., Moor B.B., Weaver D.L., Klein P. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. JAm Coll Surg 1999, 188(3):248-254.
17. Estourgie S.H., Valdes Olmos R.A., Nieweg O.E., Hoefnagel C.A., Rutgers E.J., Kroon B.B. Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br J Surg 2007, 94(9):1088-1091.
18. Krag D.N., Anderson S.J., Julian T.B., Brown A.M., Harlow S.P., Ashikaga T., et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007, 8(10):881-888.
19. Brunnert, Friedrich. Diagnosis and treatment of patients with primary and metastatic breast cancer. Ductal carcinoma in situ (DCIS). Available from: [accessed 10.11.12]. http://www.ago-online.de/de/fuer-mediziner/leitlinien/mamma/march-2012/.
20. Kreienberg R, Albert U, Follmann M, Kopp I, Kühn T, Wöckel A, et al. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapieund Nachsorge des Mammakarzinoms. Available from: [accessed 10.11.12]. http://www.dggg.de/startseite/nachrichten/s3-leitlinie-mammakarzinom/.
21. Lyman G.H., Giuliano A.E., Somerfield M.R., Benson A.B., Bodurka D.C., Burstein H.J., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. JClin Oncol 2005, 23(30):7703-7720.
22. Brennan M.E., Turner R.M., Ciatto S., Marinovich M.L., French J.R., Macaskill P., et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011, 260(1):119-128.
23. McLaughlin S.A., Wright M.J., Morris K.T., Giron G.L., Sampson M.R., Brockway J.P., et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. JClin Oncol 2008, 26(32):5213-5219.
24. Liu C.Q., Guo Y., Shi J.Y., Sheng Y. Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review. Eur J Cancer 2009, 45(9):1560-1568.
25. Ashikaga T., Krag D.N., Land S.R., Julian T.B., Anderson S.J., Brown A.M., et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. JSurg Oncol 2010, 102(2):111-118.